- To cut dependency on china drugs and boost the ‘Make in India’ program, Government of India is planning to provide some incentives based packages to both state-run and private companies to produce ingredients that are used medicines.
- It is also planning to revive two sick public sector units involved in production of active pharmaceutical ingredients (APIs)
- Currently India is importing 85% of its bulk drugs from China
- A committee headed by former health secretary VM Katoch proposed setting up of mega parks for APIs, revival of public sector units to make select and critical drugs such as penicillin and paracetamol, and financial incentives to promote the local bulk drugs sector.
- Karnataka Antibiotics & Pharmaceuticals, Rajasthan Drugs and Pharmaceuticals, Hindustan Antibiotics, Bengal Chemicals & Pharmaceuticals and Indian Drugs and Pharmaceuticals (IDPL) are five central government run units, out of which the first two have been making profit.
Source: Economic Times